BioSpace News Archive

Biofrontera Inc. announces it will report financial results for the three and six months ended June 30, 2022 before the opening of the U.S. financial markets on Friday, August 12, 2022.

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2022 financial results after market close on Thursday, August 11, 2022.

Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD).

Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pK a ).

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes.

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 11, 2022 at 4 pm CET (10 am ET) following the announcement of results for the second quarter of 2022.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), today announced it has received approval from the Australian Human Research Ethics Committee (HREC) to expand the company’s global clinical trial to Australia, to study SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial.

BriaCell Therapeutics Corp. announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.

NeuroOne Medical Technologies Corporation will host a conference call to discuss financial results for its third quarter of fiscal 2022 ended June 30, 2022.